1. Куцемелов И.Б., Табеева Г.Р. Эпидемиология первичной головной боли (по данным популяционного исследования взрослого населения г. Ростова-на-Дону). Боль. 2004; 4 (5): 24–9.
2. Россияне борются с недомоганиями: безрецептурный препарат или народная медицина вместо визита к врачу. Исследование Nielsen. www.acnielsen.ru.
3. Стайнер Т.Дж., Пемелера К., Йенсен Р. и др. Европейские принципы ведения пациентов с наиболее распространенными формами головной боли в общей практике. Пер. с англ. М.: ОГГИ, 2010.
4. Табеева Г.Р. Ибупрофен в лечении нейрогенных болевых синдромов. Cons. Med. 2006; 8 (2): 80–2.
5. Табеева Г.Р. Головная боль – актуальная проблема клинической практики. Материалы научно-практической конференции «Нейростоматология: вчера, сегодня, завтра». М., 2012: 83–8.
6. Advisory Committee of the Primary Care Network. Patient-centered strategies for effect management of migraine. Primary Care NetworkR 2000. Springfield, MO. Avaitable http://www.primarycarenet.org. Accessed on March 2, 2003.
7. Benvenuti C, Beretta A, Longoni A, Pickvance NJ. A multicenter general practice study evaluating the efficacy and tolerance of ibuprofen in common painful conditions. Pharmatherapeutica 1984; 4 (1): 9–12.
8. Bergström S, Carlson LA, Ekelund LG, Orö L. Cardiovascular and metabolic response to infusions of prostaglandin E1 and simultaneous infusions of noradrenaline and prostaglandin E1 in man. Acta Physiol Scand 1965; 64: 332–9.
9. Caldwell JR, Crain D, Hoffmeister RT et al. Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoartritis: Comparative clinical profiles. South Med J 1983; 76 (6): 706–11.
10. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992; 32: 223–8.
11. Codisposi JR, Prior MJ, Fu M et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized-controlled trial. Headache 2001; 41: 665–79.
12. Diener H-C, Antonacci F et al. Standarts and guidelines. In: Headache care, research, and education worldwide. Olesen J, Ramadan N, eds. Oxford university press 2010: 121–44.
13. Diener HC, Bussone G, de Liano H et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24: 947–54.
14. Diamond S. Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. Headache 1983; 23: 206–10.
15. Edmeads J, Findlay H, Tugwell P et al. Impact of migraine and tension-type headache on life-style, consulting behaviour and medication use: a Canadian population. Can J Neurol Sci 1993; 20: 131–7.
16. Evers S, Afra J, Frese A et al. S. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurology 2009, 16: 968–81.
17. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43: 36–43.
18. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK- 3{beta}. Cancer Prev Res 2011; 4: 161–71.
19. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 1989; 29: 507–9.
20. Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 813–8.
21. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12: 169–71.
22. Kotilinek LA, Westerman MA, Wang Q et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008; 131: 651–64.
23. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–57.
24. Lipton RB, Diamond SD, Reed M et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638–45.
25. Lipton RB, Scher AI, Kolodner K et al. Migraine in the United States: epidemiology and patterns of healthcare use. Neurology 2002; 58: 885–94.
26. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 (Suppl. 2): 20–6.
27. Lucas C, Géraud G, Valade D et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006; 46 (5): 715–25.
28. Misra UK, Kalita J, Yadav RK. Rizatriptan vs ibuprofen in migraine: A randomised placebo-controlled trial. J Headache Pain 2007; 8: 175–9.
29. Moore N, Van Ganse E, Le Parc JM et al. The PAIN study: Paracetamol, Aspirin and Ibuprofen New tolerability study. A large-scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 89–98.
30. National Headache Foundation. Fact Sheet. Available at http://www.headaches.org. Accessed on March 3, 2003.
31. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15: 531–5.
32. OTC Products: A Study of Pharmacists’ Recommendations. Pharmacy Times 2001 (Suppl.): 10–30.
33. Parantainen J, Vapaataol H, Hokkanen E. Clinical aspects of prostaglandins and leucotrienes in migraine. Cephalalgia 1986; 6 (Suppl. 4): 95–101.
34. Rainsford KD. Fifty years since the discovery of ibuprofen Inflammopharmacol, 2011; 19: 293–7.
35. Rainsford KD. History and development of ibuprofen. In: Rainsford KD (ed) Ibuprofen. A critical bibliographic review, Chapter 1. 1999; Taylor & Francis, London; 3–24.
36. Rainsford KD, Kean WF, Ehrlich GE. Triad (GI, CV, Hepatic) composite toxicity ratings for use in assessing the overall safety of NSAIDs. Intern Med J 2008; 38 (Suppl. 2): 32.
37. Rainsford KD Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275–342.
38. Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician’s view. Cephalalgia 2000; 20 (Suppl. 2): 14–24.
39. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemo-graphic factors. J Am Med Assoc 1992; 267: 64–9.
40. Suthisisang C, Poolsup N, Kittikulsuth W et al. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother 2007; 41: 1782–91.
41. Tfelt-Hansen P, Block G, Dahlof C. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765–86.
42. Townsend KP, Pratico` D. Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005; 19: 1592–601.
43.Wenzel RG, Sarvis CA, Krause ML. Over-the counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 2003; 23: 494–505.
44. Wenzel RG, Lipton RB, Diamond ML, Cady R. Migraine Therapy: A Survey of Pharmacists’ Knowledge, Attitudes, and Practice Patterns. Headache 2005; 45: 47–52.
45. Woodman TJ, Wood PJ, Thompson AS et al. Chiral inversion of 2-arylpropionyl-CoA esters by human a-methylacyl-CoA racemase 1A (P504S) – a potential mechanism for the anti-cancer effects of ibuprofen. Chem Commun 2011; 47: 7332–4.
46. Wynne S, Djakiew D. NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK- p75(NTR) pathway. Mol Cancer Res 2010; 8: 1656–64.

Г.Р.Табеева 

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ